New oral psoriasis treatment Icotyde shows superior results over injectables, delivering clear skin with a safe, once-daily ...
The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
FDA approves icotrokinra, an oral interleukin-23 receptor antagonist, for adults and pediatric patients with moderate to ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic ...
Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas ...
When you have psoriasis — a skin disease that typically causes thick, itchy, scaly, or discolored patches of skin — finding a treatment that works for you can be a challenge. Luckily, there are more ...
"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms ...
January's approval by the Food and Drug Administration (FDA) of Amevive, the first biologic treatment for chronic plaque psoriasis, is a qualified blessing for the estimated 1.5 million Americans who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results